<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-8123</journal-id>
<journal-title><![CDATA[Revista Colombiana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Colomb.Reumatol.]]></abbrev-journal-title>
<issn>0121-8123</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-81232019000100024</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[¿Is seropositivity in patients with rheumatoid arthritis treated with adalimumab a factor to develop anti-adalimumab antibodies?]]></article-title>
<article-title xml:lang="es"><![CDATA[¿Es la seropositividad en pacientes con artritis reumatoide tratados con adalimumab un factor para desarrollar anticuerpos anti-adalimumab?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez Perilla]]></surname>
<given-names><![CDATA[Aura María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vásquez]]></surname>
<given-names><![CDATA[Gloria María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[María Ximena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,CAYRE® IPS Riesgo de Fractura ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Antioquia Facultad de Medicina Grupo de Inmunología Celular e Inmunogenética]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Pontificia Universidad Javeriana Facultad de Medicina Departamento de Epidemiología Clínica]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<volume>26</volume>
<numero>1</numero>
<fpage>24</fpage>
<lpage>30</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-81232019000100024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-81232019000100024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-81232019000100024&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Objective:  To determine whether seropositivity in rheumatoid arthritis patients treated with adalimumab (ADL) is associated with the presence of anti-adalimumab (anti-ADL) antibodies.  Materials and methods:  A descriptive observational study that included patients diagnosed with rheumatoid arthritis according to ACR 1987 criteria, and who were on treatment with ADL as the first biological, for at least six months. All patients were evaluated for rheumatoid factor, anti-citrulline antibodies, erythrocyte sedimentation rate, C-reactive protein, clinimetric indices, and level of anti-ADL antibodies.  Results:  A total of 80 patients with a mean age of 56 years were evaluated, of whom 86% were women. The mean duration of the disease was 15 years, and the ADL exposure time was 52 months (median value). The seropositivity for rheumatoid factor tended to be higher in patients who developed anti-ADL antibodies compared to those who did not (90.5% vs. 66.1%). The magnitude of the association between rheumatoid factor and the presence of anti-ADL antibodies was shown to be strong and statistically significant (OR = 4.87, 95% CI; 1.03-23.03). Adjusted multivariate regression analyses showed a strong association (OR = 9.77, 95% CI; 1.74-54.79) between seropositivity and the presence of anti-ADL antibodies, which, given the low number of patients, lacks precision (95% CI very wide).  Conclusions:  Seropositive patients tend to have more anti-ADL antibodies. However, a larger sample size is required to obtain the necessary precision and greater certainty in these findings.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo:  Determinar si la seropositividad en pacientes con artritis reumatoide tratados con adalimumab (ADL), se asocia a la presencia de anticuerpos anti-adalimumab (anti-ADL).  Materiales y métodos:  Es un estudio observacional descriptivo que incluyó pacientes con diagnóstico de artritis reumatoide según criterios ACR1987, que estaban en tratamiento con ADL como primer biológico, por al menos 6 meses. Todos los pacientes se evaluaron para factor reumatoide, anticuerpos anticitrulina, velocidad de sedimentación globular, proteína C reactiva, índices clinimétricos y nivel de anticuerpos anti-ADL.  Resultados:  Se evaluaron 80 pacientes con edad promedio de 56 arios, el 86% fueron mujeres, la duración promedio de la enfermedad fue de 15 años y el tiempo de exposición a ADL de 52 meses (valor mediano). La seropositividad para factor reumatoide tendió a ser mayor en los pacientes que desarrollaron anticuerpos anti-ADL en comparación con los que no (90,5% vs. 66,1%). La magnitud de la asociación entre factor reumatoide y la presencia de anticuerpos anti-ADL tendió a ser fuerte y estadísticamente significativa (OR = 4,87; IC 95%: 1,03-23,03). Los análisis ajustados de regresión multivariable mostraron una asociación fuerte (OR = 9,77; IC 95%: 1,74-54,79) entre la seropositividad y la presencia de anticuerpos anti-ADL, que dado el bajo número de pacientes carece de precisión (IC 95% muy amplios).  Conclusiones:  Los pacientes seropositivos tienden a presentar más anticuerpos anti-ADL; sin embargo, se requiere tener un mayor tamaño muestral para obtener la precisión necesaria y tener mayor certeza en estos hallazgos.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[Biological therapy]]></kwd>
<kwd lng="en"><![CDATA[Immunogenicity]]></kwd>
<kwd lng="en"><![CDATA[Adalimumab]]></kwd>
<kwd lng="en"><![CDATA[Anti-adalimumab antibodies]]></kwd>
<kwd lng="es"><![CDATA[Artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[Terapia biológica]]></kwd>
<kwd lng="es"><![CDATA[Inmunogenicidad]]></kwd>
<kwd lng="es"><![CDATA[Adalimumab]]></kwd>
<kwd lng="es"><![CDATA[Anticuerpos anti-adalimumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Louie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Broder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.]]></article-title>
<source><![CDATA[Curr Rheumatol Rep]]></source>
<year>2005</year>
<numero>7</numero>
<issue>7</issue>
<page-range>3-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McInnes]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Schett]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytokines in the pathogenesis of rheumatoid arthritis]]></article-title>
<source><![CDATA[Nat Rev Immunol]]></source>
<year>2007</year>
<numero>7</numero>
<issue>7</issue>
<page-range>429-42</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thalayasingam]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Isaacs]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-TNF therapy]]></article-title>
<source><![CDATA[Best Pract Res Clin Rheumatol]]></source>
<year>2011</year>
<numero>25</numero>
<issue>25</issue>
<page-range>549-67</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cludts]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Spinelli]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Morello]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hockley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Valesini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wadhwa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab]]></article-title>
<source><![CDATA[Cytokine]]></source>
<year>2017</year>
<numero>96</numero>
<issue>96</issue>
<page-range>16-23</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Morand]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mackay]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mariette]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Marcelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2013</year>
<numero>72</numero>
<issue>72</issue>
<page-range>165-78</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bandrés Ciga]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Salvatierra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López-Sidro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García-Sánchez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Durán]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vives]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies]]></article-title>
<source><![CDATA[J Clin Rheumatol]]></source>
<year>2015</year>
<numero>21</numero>
<issue>21</issue>
<page-range>115-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartelds]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Wijbrandts]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Nurmohamed]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Stapel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lems]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Aarden]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2010</year>
<numero>69</numero>
<issue>69</issue>
<page-range>817-21</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Schouwenburg]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Rispens]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wolbink]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2013</year>
<numero>9</numero>
<issue>9</issue>
<page-range>164-72</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcés]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Demengeot]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Benito-García]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2012</year>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcés]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Benito-García]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[da Silva]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Aarden]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Demengeot]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartelds]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Krieckaert]]></surname>
<given-names><![CDATA[CLM]]></given-names>
</name>
<name>
<surname><![CDATA[Nurmohamed]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[van Schouwenburg]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Lems]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Twisk]]></surname>
<given-names><![CDATA[JWR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up]]></article-title>
<source><![CDATA[Heal (San Fr)]]></source>
<year>2011</year>
<numero>305</numero>
<issue>305</issue>
<page-range>1460-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cabez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Balsa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sanmarti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concise report: drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2018</year>
<numero>75</numero>
<issue>75</issue>
<page-range>688-93</page-range><publisher-loc><![CDATA[Oxford ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strand]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Balsa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Saleh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barile-Fabris]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Horiuchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Takeuchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity of biologics in chronic inflammatory diseases: a systematic review]]></article-title>
<source><![CDATA[BioDrugs]]></source>
<year>2017</year>
<numero>31</numero>
<issue>31</issue>
<page-range>299-316</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnett]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Edworthy]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Bloch]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[McShane]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fries]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>1988</year>
<numero>31</numero>
<issue>31</issue>
<page-range>315-24</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aletaha]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Neogi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Silman]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Funovits]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Felson]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Bingham]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative]]></article-title>
<source><![CDATA[Ann Rheum Dis. 2010]]></source>
<year>2010</year>
<numero>69</numero>
<issue>69</issue>
<page-range>1580-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerlag]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Raza]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[van Baarsen]]></surname>
<given-names><![CDATA[LGM]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2012</year>
<numero>71</numero>
<issue>71</issue>
<page-range>638-41</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ajeganova]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huizinga]]></surname>
<given-names><![CDATA[TWJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seronegative and seropositive RA: alike but different?]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2015</year>
<numero>11</numero>
<issue>11</issue>
<page-range>8-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirino]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Remmers]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic architectures of seropositive and seronegative rheumatic diseases]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2015</year>
<numero>11</numero>
<issue>11</issue>
<page-range>401-14</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keiserman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Codreanu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Handa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Xibille-Friedmann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mysler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Briceiio]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences]]></article-title>
<source><![CDATA[Expert Rev Clin Immunol]]></source>
<year>2014</year>
<numero>10</numero>
<issue>10</issue>
<page-range>1049-57</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartelds]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Wijbrandts]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Nurmohamed]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Stapel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lems]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Aarden]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2007</year>
<numero>66</numero>
<issue>66</issue>
<page-range>921-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartelds]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Wijbrandts]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Nurmohamed]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Wolbink]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[de Vries]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tak]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms]]></article-title>
<source><![CDATA[Artritis Rheum]]></source>
<year>2009</year>
<numero>60</numero>
<issue>60</issue>
<page-range>2541-2</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anaya]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Pineda-Tamayo]]></surname>
<given-names><![CDATA[RGL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Artritis reumatoide]]></article-title>
<source><![CDATA[Bases moleculares, clínicas y terapéuticas]]></source>
<year>2006</year>
<page-range>161-88</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaeverbeke]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Truchetet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kostine]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barnetche]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bannwarth]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Richez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review: immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2016</year>
<page-range>210-20</page-range><publisher-loc><![CDATA[Oxford ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Promonitor]]></article-title>
<source><![CDATA[Anti-ADL Ref. 5090130000]]></source>
<year>2014</year>
<page-range>1-17</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
